|
Michael E. Hanson
24 years experience with Eli Lilly and
Company, where he was President of the Internal Medicine
Business Unit (Cardiovascular and Oncology) and served
on the Operations Committee. Prior positions include
Vice President of Lilly Research Laboratories, Vice
President of New Product Planning and Licensing, Vice
President of Eli Lilly International, and President
and GM of Lilly Japan. He is currently on the board
of a number of early-stage life science companies including
GlycoGenesis, Sound Technologies, Inc., Z-29, Inc.,
and was a past board member of MGI Pharma. He has a
BS in Pharmacy from North Dakota State University, Fargo,
a MS in Hospital Pharmacy Administration, University
of Minnesota, Minneapolis and attended the Advanced
Management Program at Harvard Business School.
|